<p>Guardant Health（納斯達克股票代碼：GH - 獲取免費報告）在週五發佈的報告中，摩根大通將其目標價格從 130.00 美元上調至 135.00 美元，Benzinga 報道。該公司目前對該股票給予 “增持” 評級。摩根大通的目標價格暗示該股票相較於之前收盤價有 47.11% 的潛在上漲空間。</p>
<p>獲取 <strong>Guardant Health</strong> 的最新提醒：</p>
<ul>
<li>4 只醫療股大幅上漲——還有更多上漲空間</li>
</ul>
<p>其他幾家券商也對 GH 發表了評論。Stifel Nicolaus 將 Guardant Health 的目標價格從 120.00 美元上調至 130.00 美元，並在 2 月 20 日的報告中給予該公司 “買入” 評級。Canaccord Genuity Group 將 Guardant Health 的目標價格從 125.00 美元上調至 135.00 美元，並在 2 月 20 日的研究報告中給予該公司 “買入” 評級。花旗集團將 Guardant Health 的目標價格從 135.00 美元上調至 150.00 美元，並在 2 月 20 日的研究報告中給予該公司 “買入” 評級。富國銀行將 Guardant Health 的目標價格從 120.00 美元上調至 125.00 美元，並在 2 月 20 日的報告中給予該股票 “增持” 評級。最後，Raymond James Financial 在 2 月 23 日的研究報告中重申了 “跑贏大盤” 評級，並設定了 129.00 美元的目標價格。十九位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Guardant Health 目前的共識評級為 “適度買入”，共識目標價格為 129.16 美元。</p>
<p><strong>查看我們對 GH 的最新分析</strong></p>
<h2>Guardant Health 股價下跌 0.5%</h2>
<ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
<p>週五交易時，Guardant Health 的股票下跌 0.50 美元，報 91.77 美元。該股票的交易量為 1,737,746 股，而其平均交易量為 2,037,164 股。該股票的 50 日移動平均線為 88.93 美元，200 日移動平均線為 96.92 美元。Guardant Health 的 12 個月低點為 36.36 美元，12 個月高點為 120.74 美元。該公司的市值為 121.7 億美元，市盈率為-27.68，貝塔值為 1.48。</p>
<p>Guardant Health（納斯達克股票代碼：GH - 獲取免費報告）最後一次發佈財報是在 2 月 19 日。該公司報告本季度每股收益（EPS）為-0.50 美元，低於分析師的共識預期-0.43 美元，差距為 0.07 美元。該公司本季度的收入為 2.8127 億美元，而分析師預期為 2.6974 億美元。該公司的季度收入同比增長 39.4%。在去年同期，該公司每股收益為-0.62 美元。整體來看，賣方分析師預測 Guardant Health 在本年度的每股收益將為-2.87 美元。</p>
<h2>Guardant Health 的內部買賣情況</h2>
<ul>
<li>3 只快速增長的股票分析師預計價格將翻倍</li>
</ul>
<p>在其他新聞中，首席財務官 Michael Brian Bell 於 3 月 16 日星期一出售了 3,000 股該公司的股票，交易價格為 87.04 美元，總價值為 261,120.00 美元。交易後，首席財務官直接持有該公司 43,601 股股票，價值約為 3,795,031.04 美元。此次交易代表其持股比例減少了 6.44%。該交易已在 SEC 的備案中披露，具體信息可在此鏈接查看。此外，董事 Medina Manuel Hidalgo 於 3 月 6 日星期五出售了 1,300 股該公司的股票，交易價格為 91.54 美元，總交易額為 119,002.00 美元。交易後，該董事在公司持有 1,193 股，價值為 109,207.22 美元。此次交易使其持股比例減少了 52.15%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去的 90 天內，內部人士已出售 8,596 股公司股票，價值 775,767 美元。目前，6.10% 的股票由公司內部人士持有。</p>
<h2>機構投資者對 Guardant Health 的看法</h2>
<p>一些大型投資者最近對 GH 的持倉進行了調整。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Guardant Health 的持倉提高了 2.1%。先鋒集團目前持有該公司 12,160,768 股股票，價值 1,242,101,000 美元，之前在上一季度又購買了 251,939 股。T. Rowe Price Associates Inc. MD 在第四季度將其在 Guardant Health 的持倉增加了 33.5%。T. Rowe Price Associates Inc. MD 目前持有該公司 5,636,078 股股票，價值 575,670,000 美元，之前在上一季度又購買了 1,414,441 股。Baillie Gifford &amp; Co.在第三季度將其在 Guardant Health 的持倉增加了 6.6%。Baillie Gifford &amp; Co.目前持有該公司 5,127,692 股股票，價值 320,378,000 美元，之前在上一季度又收購了 317,906 股。富蘭克林資源公司（Franklin Resources Inc.）在第四季度將其在 Guardant Health 的持倉提高了 14.9%。富蘭克林資源公司目前持有該公司 3,361,547 股股票，價值 343,348,000 美元，之前在該期間又收購了 435,232 股。最後，Geode Capital Management LLC 在第四季度將其在 Guardant Health 的持倉提高了 9.4%。Geode Capital Management LLC 目前持有該公司 3,213,657 股股票，價值 328,297,000 美元，之前在該期間又收購了 277,001 股。目前 92.60% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Guardant Health 的關鍵新聞</h2>
<p>以下是本週影響 Guardant Health 的關鍵新聞：</p>
<ul>
<li>積極情緒：2026 年第一季度收入和增長大幅超出預期——收入為 3.017 億美元，同比增長約 48%；腫瘤學收入為 2.05 億美元，檢測量增長約 47%（約 86,000 個腫瘤學檢測），顯示出強勁的需求。Guardant Health 發佈 2026 年第一季度財務結果</li>
<li>積極情緒：公司提高了 2026 財年的收入指引（大約在 13 億美元範圍內），這支持了未來收入的可見性，並支撐了股價的上漲。指引新聞稿</li>
<li>積極情緒：每股收益略好於預期——報告每股虧損為（0.45 美元），而市場共識約為（0.47 美元），這一小幅超出降低了近期因盈利意外帶來的下行風險。Zacks：第一季度虧損，超出收入預期</li>
<li>中性情緒：管理層的評論和細節可供查閲——投資者可以查看收益幻燈片和完整的收益電話會議記錄，以評估利潤率軌跡、指引驅動因素和商業化節奏。收益電話會議記錄第一季度幻燈片</li>
<li>消極情緒：公司在每股收益方面仍然處於虧損狀態，市場共識仍然預期全年每股收益為負（分析師預測持續虧損），因此估值依賴於持續的收入執行和盈利能力的進展。第一季度財報快照</li>
<li>消極情緒：今天的交易仍然有些波動，成交量低於平均水平——如果未來幾個季度未能達到高預期，請關注流動性和財報後的賣壓。MSN 報道</li>
</ul>
<h2>Guardant Health 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Guardant Health, Inc 是一家專注於血液癌症診斷的精準腫瘤學公司。成立於 2012 年，總部位於加利福尼亞州紅木城，該公司開發了使用循環腫瘤 DNA（ctDNA）對實體腫瘤患者的基因組變化進行分析的非侵入性檢測。Guardant Health 的使命是通過向全球臨牀醫生、製藥合作伙伴和研究人員提供可操作的數據來推動癌症護理的進步。</p>
<p>公司的旗艦產品 Guardant360 是一種下一代測序（NGS）檢測，旨在檢測 70 多種與癌症相關的基因中的突變、拷貝數變化和特定融合。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Guardant Health 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
<p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Guardant Health 並不在名單上。</p>
<p>雖然 Guardant Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

2 倍做多納斯達克生物技術 ETF - ProShares

醫療業 ETF - SPDR

<p>摩根大通已將 Guardant Health（納斯達克代碼：GH）的目標股價從 130 美元上調至 135 美元，維持 “增持” 評級。這表明該股相較於前一交易日收盤價有 47.11% 的潛在上漲空間。其他券商也提高了目標股價，普遍評級為 “適度買入”，目標價為 129.16 美元。Guardant Health 的股價下跌 0.5%，至 91.77 美元，市值為 121.7 億美元。儘管未能達到每股收益預期，該公司報告的收入同比增長 39.4%</p>

<p>Guardant Health (NASDAQ:GH - Get Free Report) had its price objective lifted by research analysts at JPMorgan Chase &amp; Co. from $130.00 to $135.00 in a report issued on Friday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target would suggest a potential upside of 47.11% from the stock's previous close.</p>
<div class="lb-trans"><p>Guardant Health（納斯達克股票代碼：GH - 獲取免費報告）在週五發佈的報告中，摩根大通將其目標價格從 130.00 美元上調至 135.00 美元，Benzinga 報道。該公司目前對該股票給予 “增持” 評級。摩根大通的目標價格暗示該股票相較於之前收盤價有 47.11% 的潛在上漲空間。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Guardant Health</strong> 的最新提醒：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只醫療股大幅上漲——還有更多上漲空間</li>
</ul>
</div><p>Several other brokerages have also commented on GH. Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 20th. Canaccord Genuity Group increased their target price on Guardant Health from $125.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, February 20th. Citigroup lifted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 20th. Wells Fargo &amp; Company boosted their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 20th. Finally, Raymond James Financial restated an &#34;outperform&#34; rating and set a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Guardant Health currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $129.16.</p>
<div class="lb-trans"><p>其他幾家券商也對 GH 發表了評論。Stifel Nicolaus 將 Guardant Health 的目標價格從 120.00 美元上調至 130.00 美元，並在 2 月 20 日的報告中給予該公司 “買入” 評級。Canaccord Genuity Group 將 Guardant Health 的目標價格從 125.00 美元上調至 135.00 美元，並在 2 月 20 日的研究報告中給予該公司 “買入” 評級。花旗集團將 Guardant Health 的目標價格從 135.00 美元上調至 150.00 美元，並在 2 月 20 日的研究報告中給予該公司 “買入” 評級。富國銀行將 Guardant Health 的目標價格從 120.00 美元上調至 125.00 美元，並在 2 月 20 日的報告中給予該股票 “增持” 評級。最後，Raymond James Financial 在 2 月 23 日的研究報告中重申了 “跑贏大盤” 評級，並設定了 129.00 美元的目標價格。十九位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Guardant Health 目前的共識評級為 “適度買入”，共識目標價格為 129.16 美元。</p>
</div><p><strong>View Our Latest Analysis on GH</strong></p>
<div class="lb-trans"><p><strong>查看我們對 GH 的最新分析</strong></p>
</div><h2>Guardant Health Trading Down 0.5%</h2>
<div class="lb-trans"><h2>Guardant Health 股價下跌 0.5%</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
</div><p>Shares of Guardant Health stock traded down $0.50 during trading hours on Friday, reaching $91.77. The stock had a trading volume of 1,737,746 shares, compared to its average volume of 2,037,164. The stock's 50 day moving average is $88.93 and its 200 day moving average is $96.92. Guardant Health has a twelve month low of $36.36 and a twelve month high of $120.74. The firm has a market capitalization of $12.17 billion, a PE ratio of -27.68 and a beta of 1.48.</p>
<div class="lb-trans"><p>週五交易時，Guardant Health 的股票下跌 0.50 美元，報 91.77 美元。該股票的交易量為 1,737,746 股，而其平均交易量為 2,037,164 股。該股票的 50 日移動平均線為 88.93 美元，200 日移動平均線為 96.92 美元。Guardant Health 的 12 個月低點為 36.36 美元，12 個月高點為 120.74 美元。該公司的市值為 121.7 億美元，市盈率為-27.68，貝塔值為 1.48。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. The firm's revenue for the quarter was up 39.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.62) EPS. As a group, sell-side analysts predict that Guardant Health will post -2.87 earnings per share for the current year.</p>
<div class="lb-trans"><p>Guardant Health（納斯達克股票代碼：GH - 獲取免費報告）最後一次發佈財報是在 2 月 19 日。該公司報告本季度每股收益（EPS）為-0.50 美元，低於分析師的共識預期-0.43 美元，差距為 0.07 美元。該公司本季度的收入為 2.8127 億美元，而分析師預期為 2.6974 億美元。該公司的季度收入同比增長 39.4%。在去年同期，該公司每股收益為-0.62 美元。整體來看，賣方分析師預測 Guardant Health 在本年度的每股收益將為-2.87 美元。</p>
</div><h2>Insider Buying and Selling at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的內部買賣情況</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師預計價格將翻倍</li>
</ul>
</div><p>In other news, CFO Michael Brian Bell sold 3,000 shares of the firm's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the transaction, the chief financial officer directly owned 43,601 shares of the company's stock, valued at approximately $3,795,031.04. This trade represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the business's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the transaction, the director owned 1,193 shares in the company, valued at $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,596 shares of company stock valued at $775,767 over the last ninety days. 6.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Michael Brian Bell 於 3 月 16 日星期一出售了 3,000 股該公司的股票，交易價格為 87.04 美元，總價值為 261,120.00 美元。交易後，首席財務官直接持有該公司 43,601 股股票，價值約為 3,795,031.04 美元。此次交易代表其持股比例減少了 6.44%。該交易已在 SEC 的備案中披露，具體信息可在此鏈接查看。此外，董事 Medina Manuel Hidalgo 於 3 月 6 日星期五出售了 1,300 股該公司的股票，交易價格為 91.54 美元，總交易額為 119,002.00 美元。交易後，該董事在公司持有 1,193 股，價值為 109,207.22 美元。此次交易使其持股比例減少了 52.15%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去的 90 天內，內部人士已出售 8,596 股公司股票，價值 775,767 美元。目前，6.10% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Guardant Health</h2>
<div class="lb-trans"><h2>機構投資者對 Guardant Health 的看法</h2>
</div><p>A number of large investors have recently made changes to their positions in GH. Vanguard Group Inc. lifted its position in Guardant Health by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company's stock worth $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company's stock valued at $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Baillie Gifford &amp; Co. increased its stake in shares of Guardant Health by 6.6% in the 3rd quarter. Baillie Gifford &amp; Co. now owns 5,127,692 shares of the company's stock worth $320,378,000 after acquiring an additional 317,906 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company's stock worth $343,348,000 after acquiring an additional 435,232 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Guardant Health by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company's stock worth $328,297,000 after acquiring an additional 277,001 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投資者最近對 GH 的持倉進行了調整。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Guardant Health 的持倉提高了 2.1%。先鋒集團目前持有該公司 12,160,768 股股票，價值 1,242,101,000 美元，之前在上一季度又購買了 251,939 股。T. Rowe Price Associates Inc. MD 在第四季度將其在 Guardant Health 的持倉增加了 33.5%。T. Rowe Price Associates Inc. MD 目前持有該公司 5,636,078 股股票，價值 575,670,000 美元，之前在上一季度又購買了 1,414,441 股。Baillie Gifford &amp; Co.在第三季度將其在 Guardant Health 的持倉增加了 6.6%。Baillie Gifford &amp; Co.目前持有該公司 5,127,692 股股票，價值 320,378,000 美元，之前在上一季度又收購了 317,906 股。富蘭克林資源公司（Franklin Resources Inc.）在第四季度將其在 Guardant Health 的持倉提高了 14.9%。富蘭克林資源公司目前持有該公司 3,361,547 股股票，價值 343,348,000 美元，之前在該期間又收購了 435,232 股。最後，Geode Capital Management LLC 在第四季度將其在 Guardant Health 的持倉提高了 9.4%。Geode Capital Management LLC 目前持有該公司 3,213,657 股股票，價值 328,297,000 美元，之前在該期間又收購了 277,001 股。目前 92.60% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Key Guardant Health News</h2>
<div class="lb-trans"><h2>Guardant Health 的關鍵新聞</h2>
</div><p>Here are the key news stories impacting Guardant Health this week:</p>
<div class="lb-trans"><p>以下是本週影響 Guardant Health 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Q1 revenue and growth materially beat expectations — revenue was $301.7M, up ~48% year-over-year; oncology revenue was $205M and test volume rose ~47% (≈86k oncology tests), signaling strong demand. Guardant Health Reports First Quarter 2026 Financial Results</li>
<li>Positive Sentiment: Company raised FY2026 revenue guidance (roughly to the ~$1.3B range), which supports forward revenue visibility and underpins the share-price rally. Guidance Press Release</li>
<li>Positive Sentiment: EPS slightly better than estimates — reported loss per share of ($0.45) vs. consensus around ($0.47), a modest beat that reduces near-term downside risk from earnings surprises. Zacks: Q1 Loss, Beats Revenue Estimates</li>
<li>Neutral Sentiment: Management commentary and detail are available — investors can review the earnings slide deck and the full earnings call transcript to assess margin trajectory, guidance drivers, and commercialization cadence. Earnings Call TranscriptQ1 Slide Deck</li>
<li>Negative Sentiment: Company remains unprofitable on an EPS basis and consensus still expects negative full-year EPS (analysts forecast continued losses), so valuation depends on sustained top-line execution and progress toward profitability. Q1 Earnings Snapshot</li>
<li>Negative Sentiment: Trading remains somewhat volatile and below average volume today versus typical averages — keep an eye on liquidity and post-earnings selling pressure if future quarters miss elevated expectations. MSN Coverage</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：2026 年第一季度收入和增長大幅超出預期——收入為 3.017 億美元，同比增長約 48%；腫瘤學收入為 2.05 億美元，檢測量增長約 47%（約 86,000 個腫瘤學檢測），顯示出強勁的需求。Guardant Health 發佈 2026 年第一季度財務結果</li>
<li>積極情緒：公司提高了 2026 財年的收入指引（大約在 13 億美元範圍內），這支持了未來收入的可見性，並支撐了股價的上漲。指引新聞稿</li>
<li>積極情緒：每股收益略好於預期——報告每股虧損為（0.45 美元），而市場共識約為（0.47 美元），這一小幅超出降低了近期因盈利意外帶來的下行風險。Zacks：第一季度虧損，超出收入預期</li>
<li>中性情緒：管理層的評論和細節可供查閲——投資者可以查看收益幻燈片和完整的收益電話會議記錄，以評估利潤率軌跡、指引驅動因素和商業化節奏。收益電話會議記錄第一季度幻燈片</li>
<li>消極情緒：公司在每股收益方面仍然處於虧損狀態，市場共識仍然預期全年每股收益為負（分析師預測持續虧損），因此估值依賴於持續的收入執行和盈利能力的進展。第一季度財報快照</li>
<li>消極情緒：今天的交易仍然有些波動，成交量低於平均水平——如果未來幾個季度未能達到高預期，請關注流動性和財報後的賣壓。MSN 報道</li>
</ul>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家專注於血液癌症診斷的精準腫瘤學公司。成立於 2012 年，總部位於加利福尼亞州紅木城，該公司開發了使用循環腫瘤 DNA（ctDNA）對實體腫瘤患者的基因組變化進行分析的非侵入性檢測。Guardant Health 的使命是通過向全球臨牀醫生、製藥合作伙伴和研究人員提供可操作的數據來推動癌症護理的進步。</p>
</div><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p>
<div class="lb-trans"><p>公司的旗艦產品 Guardant360 是一種下一代測序（NGS）檢測，旨在檢測 70 多種與癌症相關的基因中的突變、拷貝數變化和特定融合。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Guardant Health 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Guardant Health 並不在名單上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Guardant Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Market Beat

Guardant Health

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

美國醫療保健供應商 ETF - iShares

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

基因免疫&健康關懷 ETF - iShares

標普生物技術 3 倍做多 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

美國醫藥設備 ETF - iShares

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

摩根大通

Stifel Financial

花旗

富國銀行

瑞傑金融

普信金融

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

CITIGROUP INC 6.250 NON CUM SER II PFD WI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

摩根大通預測 Guardant Health（納斯達克股票代碼：GH）的股票將迎來強勁的價格升值